Han Xinpu, Song Xiaotong, Xiao Zhigang, Zhu Guanghui, Gao Ruike, Ni Baoyi, Li Jie
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Department of Hematology-Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Front Cell Dev Biol. 2024 Feb 9;12:1310442. doi: 10.3389/fcell.2024.1310442. eCollection 2024.
Myeloid-derived suppressor cells (MDSCs) are key immunosuppressive cells in the tumor microenvironment (TME) that play critical roles in promoting tumor growth and metastasis. Tumor-associated platelets (TAPs) help cancer cells evade the immune system and promote metastasis. In this paper, we describe the interaction between MDSCs and TAPs, including their generation, secretion, activation, and recruitment, as well as the effects of MDSCs and platelets on the generation and changes in the immune, metabolic, and angiogenic breast cancer (BC) microenvironments. In addition, we summarize preclinical and clinical studies, traditional Chinese medicine (TCM) therapeutic approaches, and new technologies related to targeting and preventing MDSCs from interacting with TAPs to modulate the BC TME, discuss the potential mechanisms, and provide perspectives for future development. The therapeutic strategies discussed in this review may have implications in promoting the normalization of the BC TME, reducing primary tumor growth and distant lung metastasis, and improving the efficiency of anti-tumor therapy, thereby improving the overall survival (OS) and progression-free survival (PFS) of patients. However, despite the significant advances in understanding these mechanisms and therapeutic strategies, the complexity and heterogeneity of MDSCs and side effects of antiplatelet agents remain challenging. This requires further investigation in future prospective cohort studies.
髓源性抑制细胞(MDSCs)是肿瘤微环境(TME)中的关键免疫抑制细胞,在促进肿瘤生长和转移中发挥着重要作用。肿瘤相关血小板(TAPs)帮助癌细胞逃避免疫系统并促进转移。在本文中,我们描述了MDSCs与TAPs之间的相互作用,包括它们的产生、分泌、激活和募集,以及MDSCs和血小板对免疫、代谢和血管生成性乳腺癌(BC)微环境的产生和变化的影响。此外,我们总结了临床前和临床研究、中医(TCM)治疗方法以及与靶向和阻止MDSCs与TAPs相互作用以调节BC TME相关的新技术,讨论了潜在机制,并为未来发展提供了展望。本综述中讨论的治疗策略可能对促进BC TME的正常化、减少原发性肿瘤生长和远处肺转移以及提高抗肿瘤治疗效率具有重要意义,从而改善患者的总生存期(OS)和无进展生存期(PFS)。然而,尽管在理解这些机制和治疗策略方面取得了重大进展,但MDSCs的复杂性和异质性以及抗血小板药物的副作用仍然具有挑战性。这需要在未来的前瞻性队列研究中进一步调查。